Condition
Agnogenic Myeloid Metaplasia
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07362225Recruiting
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
NCT00255346Phase 2Completed
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00136409Phase 2Completed
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
NCT00088231Phase 1Completed
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00506402Phase 1Completed
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Showing all 5 trials